liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Obesity: Pathophysiology and Clinical
BioApplication Enterprises, Winnipeg, Canada.
Manitoba Institute of Cell Biology, CancerCare Manitoba; Department of Human Genetics, University of Aarhus, Aarhus, Denmark.
Department of Immunology, Lerner Research Institute, Cleveland, USA.
Interfaculty Institute for Biochemistry, University of Tübingen, Germany; BioApplications Enterprises, Winnipeg, MB, Canada.ORCID iD: 0000-0001-9518-1411
2009 (English)In: Current Medicinal Chemistry, ISSN 0929-8673, Vol. 16, no 4, 506-521 p.Article in journal (Refereed) Published
Abstract [en]

Obesity is an increasingly serious socioeconomic and clinical problem. Between 1/4 - 1/3 of population in the developed countries can be classified as obese. Four major etiological factors for development of obesity are genetic determinants, environmental factors, food intake and exercise. Obesity increases the risk of the development of various pathologic conditions including: insulin-resistant diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver disease, endocrine problems, and certain forms of cancer. Thus, obesity is a negative determinant for longevity. In this review we provide broad overview of pathophysiology of obesity. We also discuss various available, and experimental therapeutic methods. We highlight functions of adipocytes including fat storing capacity and secretory activity resulting in numerous endocrine effects like leptin, IL-6, adiponectin, and resistin. The anti-obesity drugs are classified according to their primary action on energy balance. Major classes of these drugs are: appetite suppressants, inhibitors of fat absorption (i.e. orlistat), stimulators of thermogenesis and stimulators of fat mobilization. The appetite suppressants are further divided into noradrenergic agents, (i.e. phentermine, phendimetrazine, benzphetamine, diethylpropion), serotoninergic agents (i.e. dexfenfluramine), and mixed noradrenergic-serotoninergic agents (i.e. sibutramine). Thus, we highlight recent advances in the understanding of the central neural control of energy balance, current treatment strategies for obesity and the most promising targets for the development of novel anti-obesity drugs.

Place, publisher, year, edition, pages
Bentham Science , 2009. Vol. 16, no 4, 506-521 p.
Keyword [en]
BMI; BVT.933; growth hormone; TNF; PRDM16
National Category
Physiology Public Health, Global Health, Social Medicine and Epidemiology Biochemistry and Molecular Biology
URN: urn:nbn:se:liu:diva-86914DOI: 10.2174/092986709787315568ISI: 000263294900006PubMedID: 19199918OAI: diva2:583167
Available from: 2013-01-07 Created: 2013-01-07 Last updated: 2013-09-03

Open Access in DiVA

fulltext(530 kB)9553 downloads
File information
File name FULLTEXT01.pdfFile size 530 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wiechec, EmiliaLos, Marek Jan
In the same journal
Current Medicinal Chemistry
PhysiologyPublic Health, Global Health, Social Medicine and EpidemiologyBiochemistry and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 9553 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 507 hits
ReferencesLink to record
Permanent link

Direct link